secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2026-08-03T20:05:21+00:00
Accession:  0001193125-26-330541
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q2 revenue $10.9M (+18% YoY); revises 2026 guidance to $48-52M
-------------------------------------------------------------------------------

- Q2 revenue $10.9M (+18% YoY); Biologics & Drug Delivery revenue fell 15% to $4.0M.
- Neurosurgery navigation revenue surged 62% to $5.6M on IRRA flow and software.
- Operating expenses rose 51% to $17.0M; cash at $29.4M, down from $45.9M at year-end.
- 2026 revenue guidance revised to $48-52M; company prioritizing clinical capacity and new tech.
- Multiple biopharma partners received positive FDA feedback; expects 10-15 trials enrolling in 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/0001193125-26-330541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/clpt-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer